Similar articles for PMID: 34933922

Year	Number of Results
2005	2
2006	1
2011	2
2012	4
2013	3
2014	3
2015	8
2016	10
2017	13
2018	6
2019	7
2020	15
2021	24
2022	23
2023	1
2024	0

1

Risk of Radiation Exposure to Clinical Staff from Paracenteses of Large-Volume Chylous Ascites After ¹⁷⁷Lu-DOTATATE Infusion.

Tipnis S, Rieter WJ, Henderson-Suite V, Gordon L. Tipnis S, et al. J Nucl Med Technol. 2022 Sep;50(3):274-277. doi: 10.2967/jnmt.121.262820. Epub 2021 Dec 21. J Nucl Med Technol. 2022. PMID: 34933922 Free article.

2

Survival predictors of ¹⁷⁷Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS).

Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Swiha MM, et al. J Cancer Res Clin Oncol. 2022 Jan;148(1):225-236. doi: 10.1007/s00432-021-03672-w. Epub 2021 Jun 10. J Cancer Res Clin Oncol. 2022. PMID: 34110489 Free PMC article. Clinical Trial.

3

Comparison of Two Types of Amino Acid Solutions on ¹⁷⁷Lu-Dotatate Pharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors.

Lambert M, Dierickx L, Brillouet S, Courbon F, Chatelut E. Lambert M, et al. Curr Radiopharm. 2022;15(2):164-172. doi: 10.2174/1874471015666211228123525. Curr Radiopharm. 2022. PMID: 35105299

4

Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based ¹⁷⁷Lu-DOTATATE treatment of NET patients.

Sundlöv A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, Hallqvist A, Bernhardt P, Svensson J. Sundlöv A, et al. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3830-3840. doi: 10.1007/s00259-022-05786-w. Epub 2022 Apr 22. Eur J Nucl Med Mol Imaging. 2022. PMID: 35451612 Free PMC article. Clinical Trial.

5

Efficacy and Safety of ¹⁷⁷Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.

Zidan L, Iravani A, Oleinikov K, Ben-Haim S, Gross DJ, Meirovitz A, Maimon O, Akhurst T, Michael M, Hicks RJ, Grozinsky-Glasberg S, Kong G. Zidan L, et al. J Nucl Med. 2022 Feb;63(2):218-225. doi: 10.2967/jnumed.120.260760. Epub 2021 May 28. J Nucl Med. 2022. PMID: 34049983 Free PMC article.

6

Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Strosberg J, et al. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427. N Engl J Med. 2017. PMID: 28076709 Free PMC article. Clinical Trial.

7

Evaluation of the Interaction of Amino Acid Infusion on ¹⁷⁷Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors.

Puszkiel A, Bauriaud-Mallet M, Bourgeois R, Dierickx L, Courbon F, Chatelut E. Puszkiel A, et al. Clin Pharmacokinet. 2019 Feb;58(2):213-222. doi: 10.1007/s40262-018-0674-1. Clin Pharmacokinet. 2019. PMID: 29736841 Clinical Trial.

8

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.

Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O'Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A. Delpassand ES, et al. Pancreas. 2014 May;43(4):518-25. doi: 10.1097/MPA.0000000000000113. Pancreas. 2014. PMID: 24632546 Clinical Trial.

9

Patient external dose rate after ¹⁷⁷Lu-DOTATATE therapy: factors affecting its decrease and predictive value.

Zhang-Yin J, Guilabert N, Kiffel T, Montravers F, Calais P, Lumbroso J, Talbot JN. Zhang-Yin J, et al. Int J Med Sci. 2021 May 17;18(12):2725-2735. doi: 10.7150/ijms.58680. eCollection 2021. Int J Med Sci. 2021. PMID: 34104105 Free PMC article.

10

¹⁷⁷Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors.

Das S, Al-Toubah T, El-Haddad G, Strosberg J. Das S, et al. Expert Rev Gastroenterol Hepatol. 2019 Nov;13(11):1023-1031. doi: 10.1080/17474124.2019.1685381. Epub 2019 Oct 30. Expert Rev Gastroenterol Hepatol. 2019. PMID: 31652074 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

100 results

Results by year